| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 07/31/2008 | WO2008068621A3 Combination product with ido inhibitor and tumor targeted ifn-gamma |
| 07/31/2008 | WO2008068507A3 2 -phenylamino, 6- (pyrid-3-yl) quinazoline derivatives as raf-protein kinase inhibitors in cancer treatment |
| 07/31/2008 | WO2008068429A3 Composition for the prevention and/or treatment of diseases associated with tnf and/or il-12 overexpression |
| 07/31/2008 | WO2008068423A3 P<0}{0pyrrol derivatives, preparation and use of the same in therapy<0} |
| 07/31/2008 | WO2008067403A3 Presbyopia treatment by lens alteration |
| 07/31/2008 | WO2008065444A3 Substituted quinazolines |
| 07/31/2008 | WO2008065428A3 Steroid sulphatase inhibitors for treating hormone dependent cancer |
| 07/31/2008 | WO2008065409A3 Combination for use in the treatment of cancer, comprising tamoxifen or an aromatase inhibitor |
| 07/31/2008 | WO2008065387A3 Potentiation of erythropoietin (epo) action by membrane steroid receptor agonists |
| 07/31/2008 | WO2008065282A3 Substituted pyrazoles, compositions containing these, method of production and use |
| 07/31/2008 | WO2008065282A2 Substituted pyrazoles, compositions containing these, method of production and use |
| 07/31/2008 | WO2008064133A9 Synthesis and biological activities of new tricyclic-bis-enones (tbes) |
| 07/31/2008 | WO2008063888A3 Compounds modulating c-fms and/or c-kit activity and uses therefor |
| 07/31/2008 | WO2008063867A3 Tetrahydrocyclopenta[b] indole compounds as androgen receptor modulators |
| 07/31/2008 | WO2008063639A3 Compositions and methods for preserving cells of the eye |
| 07/31/2008 | WO2008063232A3 Substituted pyrazolopyrimidines |
| 07/31/2008 | WO2008062435A3 Stabilised dosage forms of amlodipine besylate |
| 07/31/2008 | WO2008062424A3 Substituted 4,5-dihydro-1h-pyrazole derivatives as cannabinoid modulators |
| 07/31/2008 | WO2008061236A3 Sulfoximines as kinase inhibitors |
| 07/31/2008 | WO2008061226A3 Sustained-release formulations of topiramate |
| 07/31/2008 | WO2008060865A3 Compositions and methods for reducing antimicrobial resistance of microbes |
| 07/31/2008 | WO2008060626A9 Compounds for modulating trpv3 function |
| 07/31/2008 | WO2008060448A3 Small molecule pak inhibitors |
| 07/31/2008 | WO2008059223A3 Process for the synthesis of moxifloxacin hydrochloride |
| 07/31/2008 | WO2008059068A3 Carbonyl-substituted titanocenes |
| 07/31/2008 | WO2008058274A3 Use of resolvins and docosatrienes and analogues thereof for the treatment of angiogenesis and ocular neovascularization |
| 07/31/2008 | WO2008057775A3 Heterocyclic amide compounds useful as kinase inhibitors |
| 07/31/2008 | WO2008056188A3 Novel compounds and methods for their production |
| 07/31/2008 | WO2008055711A3 Use of an adenosine antagonist |
| 07/31/2008 | WO2008054693A3 Uses of tetrahydrobiopterin and derivatives thereof |
| 07/31/2008 | WO2008052139A3 Ultra low dose doxepin and methods of using the same to treat sleep disorders |
| 07/31/2008 | WO2008051795A3 Preventing or reducing oxidative stress or oxidative cell injury by the administration of a water-insoluble cellulose derivative |
| 07/31/2008 | WO2008051760A3 Combination therapy for the treatment of pain |
| 07/31/2008 | WO2008051461A3 Acne treatment composition and methods for using |
| 07/31/2008 | WO2008051282A3 Crystalline forms of 4-(2-fluorophenyl)-6-methyl-2-(piperazin-1-yl)thieno(2,3-d)pyrimidine |
| 07/31/2008 | WO2008045559A3 Methods of treating oral mucositis |
| 07/31/2008 | WO2008045267A3 Pyrazolopyrimidines as cyclin dependent kinase inhibitors |
| 07/31/2008 | WO2008045189A3 Aqueous based pharmaceutical formulations of water-soluble prodrugs of propofol |
| 07/31/2008 | WO2008042896A3 Tetra-substituted ndga derivatives via ether bonds and carbamate bonds and their synthesis and pharmaceutical use |
| 07/31/2008 | WO2008041073A3 Sustained release pharmaceutical compositions of venlafaxine and process for preparation thereof |
| 07/31/2008 | WO2008037226A3 Method of preparation of a soluble formulation of water-insoluble pentacyclic and tetracyclic terpenoids, a soluble formulation of a pentacyclic or tetracyclic terpenoid and a pharmaceutical composition containing this soluble formulation |
| 07/31/2008 | WO2008036653A3 N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
| 07/31/2008 | WO2008036459A8 Inhibitors of rho kinase |
| 07/31/2008 | WO2008036216A8 Piperidine derivatives as renin inhibitors |
| 07/31/2008 | WO2008035365A3 Rna interference mediated inhibition of aurorakinase b and its combinations as anticancer therapy |
| 07/31/2008 | WO2008033427A3 Compositions and methods for detection of lysosomal storage disease |
| 07/31/2008 | WO2008032208A3 Extended release formulation of an antiepileptic agent |
| 07/31/2008 | WO2008030359A3 Topical compositions |
| 07/31/2008 | WO2008029414A3 Use of transcription factor inhibitor in the manufacture of a medicament |
| 07/31/2008 | WO2008027932A3 Cytochrome p450 oxidase inhibitors and uses thereof |
| 07/31/2008 | WO2008027273A3 Solid citrate and tartrate salts of dpp-iv inhibitors |
| 07/31/2008 | WO2008026078A3 19-nor-vitamin d analogs with 1,2,or 3,2 heterocyclic ring |
| 07/31/2008 | WO2008025847A3 Use of c7 sugars in prevention and treatment of mycoses |
| 07/31/2008 | WO2008023283A3 Stabilized esters of lutein |
| 07/31/2008 | WO2008021211A3 Compositions and methods for modulating apoptosis in cells over-expressing bcl-2 family member proteins |
| 07/31/2008 | WO2008016793A3 Methods, compositions and articles of manufacture for contributing to the treatment of cancers |
| 07/31/2008 | WO2008013838A3 Pyridizinone derivatives |
| 07/31/2008 | WO2008013799A3 Treatment and prevention of cardiovascular disease using mast cell stabilizers |
| 07/31/2008 | WO2008011557A3 Heteroaryl inhibitors of rho kinase |
| 07/31/2008 | WO2008011087A3 Preparations of phospholipids and pharmaceuticals containing 5-amino salicylic acid for the treatment of inflammatory bowel disease |
| 07/31/2008 | WO2008009664A3 Treatment of pain |
| 07/31/2008 | WO2008008493A8 Alkyne-substituted pyridone compounds and methods of use |
| 07/31/2008 | WO2008006839A3 Combinations of flibanserin with caffeine, process for their preparation and use thereof as medicaments |
| 07/31/2008 | WO2008006713A3 Improvements relating to anti-parasitic compositions |
| 07/31/2008 | WO2008005511A3 Novel inhibitors of hepatitis c virus replication |
| 07/31/2008 | WO2008005456A3 Fused heterocyclic inhibitors of d-amino acid oxidase |
| 07/31/2008 | WO2007149283B1 Use of kw-3902 for achieving diuresis in patients with congestive heart failure and acute fluid overload |
| 07/31/2008 | WO2007141571A3 Aminothiazole derivatives as inhibitors of mark |
| 07/31/2008 | WO2007141533A3 Fkbp-l and uses thereof |
| 07/31/2008 | WO2007135380A3 Antiparasitic compounds and compositions |
| 07/31/2008 | WO2007134298A3 Therapeutic compounds and their use in cancer |
| 07/31/2008 | WO2007127010A3 Diarylthiohydantoin compounds |
| 07/31/2008 | WO2007123865A3 Treatment of inflammatory and ulcerative diseases of the bowel with opioid antagonists |
| 07/31/2008 | WO2007121453A3 2-hydroxy-1-oxo 1,2 dihydro isoquinoline chelating agents |
| 07/31/2008 | WO2007120726B1 Compositions and methods related to rad51 inactivation in the treatment of neoplastic diseases, and especially cml |
| 07/31/2008 | WO2007117272A3 Methods for treatment of hemorrhagic shock and related disorders |
| 07/31/2008 | WO2007115092A3 10-substituted cytisine derivatives and methods of use thereof |
| 07/31/2008 | WO2007114946A3 Acid-sensitive linkers for drug delivery |
| 07/31/2008 | WO2007109244A3 Novel nanoparticles for delivery of active agents |
| 07/31/2008 | WO2007109178A3 Indole derivatives as inhibitors of histone deacetylase |
| 07/31/2008 | WO2007103132A3 Method and apparatus for acne treatment using low intensity light therapy |
| 07/31/2008 | WO2007100525A3 Methods for the treatment of viral diseases |
| 07/31/2008 | WO2007095638A3 Boron-containing small molecules as anti-inflammatory agents |
| 07/31/2008 | WO2007095340A3 Small-molecule modulators of trp-p8 activity |
| 07/31/2008 | WO2007092556A3 Method of using abscisic acid to treat and prevent diseases and disorders |
| 07/31/2008 | WO2007075720A8 Topical mecamylamine formulations for ocular administration and uses thereof |
| 07/31/2008 | WO2007008563A3 Preparation of pegylated conjugates of vla-4 antagonists via a mitsunobu' s reaction |
| 07/31/2008 | WO2006135627A3 Inhibitors of akt activity |
| 07/31/2008 | WO2006084043A3 Novel chloride channel pore openers |
| 07/31/2008 | WO2003064596A8 Desaturase genes, enzymes encoded thereby, and uses thereof |
| 07/31/2008 | WO2001044293A8 Sodium channel proteins |
| 07/31/2008 | US20080183210 Supplemental spine fixation device and method |
| 07/31/2008 | US20080183142 Inflammation of the large intestine, in particular the rectum, sigmoid colon, and the descending colon, that avoids the side effects associated with the bowel irritating sulfite compounds and other antioxidants for 5-aminosalicylic acid; shelf-life upon prolonged storage |
| 07/31/2008 | US20080183123 nucleic acid composition for injection; ciliary body tissue(s) or cells and/or to the extra-ocular muscle tissue or cells; antiproliferative, antiinflammatory, antiischemic agent; neurodegenerative diseases; ocular disease, vision deffects |
| 07/31/2008 | US20080183003 Neuroprotective agents; nitrate-functional, for example 1-amino-3,5-dimethyl-7-nitrateadamantane hydrochloride |
| 07/31/2008 | US20080182993 chemical intermediate is 4-(3,5-bi (1,1- dimethylethyl-4-hydroxyphenyl)-N-methyl-2-thiazolemethylamine |
| 07/31/2008 | US20080182983 degradation of hyaluronic acid and salt with hydrolase enzymes, to a form a mixture of tetrasaccharide, then applying the mixture to chromatography columns packed with ion exchangers and elution the tetrasaccharides; heat shock protein expression promoters, antiapoptosis, cell and tissue protectants |
| 07/31/2008 | US20080182981 Method and medicament for inhibiting the expression of a given gene |
| 07/31/2008 | US20080182908 Or memantine hydrochloride; immediate release; releases less than 80% of contained memantine, within the first 60 minutes; hydroxypropyl methyl cellulose |
| 07/31/2008 | US20080182907 External pharmaceutical composition containing tramadol |